RecruitingPhase 2NCT05629702
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
Studying Glioblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Birmingham
- Principal Investigator
- Fiona Collinson, MBBS, BSc, MRCP, FRCR, PhDUniversity of Leeds
- Intervention
- Nabiximols(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2023 – 2027
Study locations (22)
- Glan Clwyd Hospital, Bodelwyddan, Denbighshire, United Kingdom
- Mount Vernon Hospital, The Hillingdon Hospitals NHS Foundation Trust, Northwood, Middlesex, United Kingdom
- Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, United Kingdom
- Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, United Kingdom
- Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
- Bristol Haematology & Oncology Centre, University Hospitals Bristol & Weston NHS Foundation Trust, Bristol, United Kingdom
- Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, United Kingdom
- Western General Hospital, NHS Lothian, Edinburgh, United Kingdom
- Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde, Glasgow, United Kingdom
- Castle Hill Hospital, Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom
- St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
- St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom
- Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
- Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
- +7 more locations on ClinicalTrials.gov
Collaborators
University of Leeds · The Brain Tumour Charity · Jazz Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05629702 on ClinicalTrials.govOther trials for Glioblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07501559A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)Jecho Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE2NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIBlack Diamond Therapeutics, Inc.
- RECRUITINGPHASE1NCT07464925A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade GliomaTetragon Biosciences Ltd
- RECRUITINGNCT07411690Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial TumorsMedical University of Warsaw
- RECRUITINGPHASE1NCT07480941Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaBeijing Biotech
- RECRUITINGPHASE2NCT07225621Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed GlioblastomaAlpheus Medical, Inc.
- RECRUITINGPHASE1, PHASE2NCT073912155G-PEARL: Paxalisib in Malignant Brain TumoursInstitute of Cancer Research, United Kingdom
- RECRUITINGNANCT07426848OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour PatientsRoyal College of Surgeons, Ireland